Residential Cognitive and Interpersonal Therapy for Social Phobia
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00326430|
Recruitment Status : Completed
First Posted : May 16, 2006
Last Update Posted : May 16, 2006
|Condition or disease||Intervention/treatment||Phase|
|Social Phobia||Behavioral: Cognitive Therapy, Interpersonal Therapy||Phase 2 Phase 3|
Social phobia typically leads to severe impairment in work and other social life, and - without treatment - it can persist for decades. Given its prevalence, severity, and chronicity, effective treatment methods are strongly needed. However, traditional psychological and pharmacological treatments have had statistically significant, but clinically limited effects (Taylor, 1996).
Based on an empirical analysis of the cognitive processes in social phobia, Clark and Wells (1995) have developed a new cognitive model. Cognitive therapy (CT) derived from this model has been found to be superior to a combination of fluoxetine and self-exposure (Clark et al., 2003).
Social phobic symptoms may be viewed as a result of more general interpersonal difficulties and interpersonal psychotherapy (IPT) can be a reasonable alternative for social phobia (Lipsitz & Markowitz, 1996). A clinical case series indicates that social phobic patients improve during interpersonal psychotherapy for social phobia (IPT-SP; Lipsitz et al., 1999.
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||80 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Residential Cognitive Therapy Versus Residential Interpersonal Therapy for Social Phobia: A Randomized Controlled Trial|
|Study Start Date :||October 2001|
|Study Completion Date :||June 2004|
- Social Avoidance
- Social Anxiety
- General Anxiety
- Interpersonal Problems
- Personality Disorders
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00326430
|Vikersund, Buskerud, Norway, N-3370|
|Study Chair:||Asle Hoffart, Dr Psychol||Modum Bad|
|Principal Investigator:||Finn-Magnus Borge, Cand Psychol||Modum Bad|